Country: Canada
Language: English
Source: Health Canada
CEFAZOLIN (CEFAZOLIN SODIUM)
TEVA CANADA LIMITED
J01DB04
CEFAZOLIN
10G
POWDER FOR SOLUTION
CEFAZOLIN (CEFAZOLIN SODIUM) 10G
INTRAVENOUS
1
Prescription
FIRST GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0109442003; AHFS:
APPROVED
2013-04-12
_Pr_ _CEFAZOLIN FOR INJECTION Product Monograph Page 1 of 21 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CEFAZOLIN FOR INJECTION POWDER FOR SOLUTION, 500 MG, 1.0 G AND 10.0 G, CEFAZOLIN (AS CEFAZOLIN SODIUM) PER VIAL Intravenous, Intramuscular USP Antibiotic Teva Canada Limited Date of Initial Authorization: 30 Novopharm Court January 19, 1995 Toronto, Ontario M1B 2K9 Date of Revision: Canada MAR 15, 2024 www.tevacanada.com Submission Control Number: 265641 _Pr_ _CEFAZOLIN FOR INJECTION (Cefazolin Sodium) Product Monograph Page 2 of 21 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 11/2020 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 1 INDICATIONS .......................................................................................................................... 3 2 CONTRAINDICATIONS ......................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ...................................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ...................................................................... 4 4.3 Reconstitution ....................................................................................................................... 6 4.4 Administration ...................................................................................................................... 8 5 OVERDOSAGE ......................................................................................................................... 8 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKA Read the complete document